{
    "clinical_study": {
        "@rank": "90604", 
        "brief_summary": {
            "textblock": "The purpose of this study is determine whether point of care coagulation testing is able to\n      map the anticoagulatory effects of new oral anticoagulants dabigatran and rivaroxaban. Used\n      as devices are thrombelastometry/-graphy (ROTEM, TEG)and multiple platelet function analyzer\n      (Multiplate)."
        }, 
        "brief_title": "Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Clot Formation and Platelet Aggregation in Point of Care Testing", 
        "detailed_description": {
            "textblock": "Patients receiving dabigatran or rivaroxaban in therapeutic doses are recruited. Blood will\n      be taken twice in correlation to the time of drug intake (before and 3 hours after drug\n      intake). The results of thrombelastometry/-graphy and multiple platelet function analyzer\n      will be  compared directly with the concentrations determined by plasma concentration\n      assays."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients receiving Dabigatran or Rivaroxaban\n\n          -  Adults > 18 years\n\n        Exclusion Criteria:\n\n          -  Patients receiving concomittantly inhibitors of platelet function\n\n          -  Renal insufficiency (Creatinine > 1,5 mg/dl), Urea > 80 mg/dl)\n\n          -  Hemodialysis\n\n          -  Hepatic Dysfunction (AST > 30 U/l, ALT > 30 U/l)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary Care Clinic. Patients with non-valvular atrial fibrillation who receive Dabigatran\n        or Rivaroxaban for prevention of stroke and systemic embolism."
            }
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01704053", 
            "org_study_id": "NOAPOC-271/12"
        }, 
        "intervention_browse": {
            "mesh_term": "Anticoagulants"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "New Oral Anticoagulants", 
            "Dabigatran", 
            "Rivaroxaban", 
            "Thrombelastometry/-graphy (ROTEM, TEG)", 
            "Multiple Platelet Function Analyzer (Multiplate)"
        ], 
        "lastchanged_date": "October 10, 2012", 
        "location": {
            "contact": {
                "email": "matthias.klages@kgu.de", 
                "last_name": "Matthias Klages, M.D.", 
                "phone": "0049 6963015998"
            }, 
            "facility": {
                "address": {
                    "city": "Frankfurt/Main", 
                    "country": "Germany", 
                    "state": "Hessen", 
                    "zip": "60590"
                }, 
                "name": "University Hospital of University hospital of Frankfurt/Main, Department of Anesthesiology, Intensive-Care Medicine and Pain Therapy"
            }, 
            "investigator": {
                "last_name": "Matthias Klages, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Monitoring The Anticoagulatory Effects of Dabigatran and Rivaroxaban On Plasmatic and Cellular Coagulation by Rotational Thrombelastometry/-Graphy and Multiple Platelet Function Analyzer", 
        "overall_contact": {
            "email": "matthias.klages@kgu.de", 
            "last_name": "Matthias Klages, M.D.", 
            "phone": "0049 6963015998"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01704053"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johann Wolfgang Goethe University Hospitals", 
            "investigator_full_name": "Dr. Matthias Klages", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Johann Wolfgang Goethe University Hospitals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johann Wolfgang Goethe University Hospitals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}